Is Reddit a Buy on the Dip?
Reddit (NYSE:RDDT) share price has been on the proverbial ropes…
Sell
22
OTLK Quote, Financials, Valuation and Earnings
Last price:
$1.57
Seasonality move
:
-8.05%
Day range:
$1.50 - $1.57
52-week range:
$0.87 - $12.85
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
4.23x
P/B ratio:
--
Volume:
351.3K
Avg. volume:
549.3K
1-year change:
-72.6%
Market cap:
$50.3M
Revenue:
--
EPS (TTM):
-$7.42
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
OTLK
Outlook Therapeutics
|
$2.3M | -$0.47 | -- | -93.45% | $10.00 |
|
BMRA
Biomerica
|
-- | -- | -- | -- | -- |
|
NBY
NovaBay Pharmaceuticals
|
$3M | -$0.21 | 14.03% | -95.43% | $0.85 |
|
OGEN
Oragenics
|
-- | -- | -- | -- | $1.00 |
|
PTN
Palatin Technologies
|
-- | -$0.19 | -100% | -67.93% | $7.00 |
|
TOVX
Theriva Biologics
|
-- | -$5.50 | -- | -8.25% | $6.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
OTLK
Outlook Therapeutics
|
$1.57 | $10.00 | $50.3M | -- | $0.00 | 0% | 4.23x |
|
BMRA
Biomerica
|
$0.63 | -- | $11.6M | -- | $0.00 | 0% | 1.91x |
|
NBY
NovaBay Pharmaceuticals
|
$0.63 | $0.85 | $3.1M | -- | $0.00 | 0% | 0.07x |
|
OGEN
Oragenics
|
$0.28 | $1.00 | $3.4M | -- | $0.00 | 0% | 1.10x |
|
PTN
Palatin Technologies
|
$0.79 | $7.00 | $20.6M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics
|
$1.15 | $6.00 | $3.2M | -- | $0.00 | 0% | 1.59x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
OTLK
Outlook Therapeutics
|
-- | -0.680 | -- | -- |
|
BMRA
Biomerica
|
-- | 1.014 | -- | 1.97x |
|
NBY
NovaBay Pharmaceuticals
|
4.54% | 0.646 | 1.51% | 0.75x |
|
OGEN
Oragenics
|
-- | 3.509 | -- | -- |
|
PTN
Palatin Technologies
|
-- | -1.737 | -- | 0.99x |
|
TOVX
Theriva Biologics
|
-- | -2.868 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
OTLK
Outlook Therapeutics
|
-- | -$21.6M | -- | -- | -- | -$11M |
|
BMRA
Biomerica
|
$437K | -$993K | -81.84% | -81.84% | -60.7% | -$824K |
|
NBY
NovaBay Pharmaceuticals
|
$1.6M | -$1.1M | -334.47% | -461.38% | -44% | -$2.1M |
|
OGEN
Oragenics
|
-- | -$2.4M | -- | -- | -- | -$2M |
|
PTN
Palatin Technologies
|
-- | -$5.1M | -- | -- | -2356.3% | -$4.8M |
|
TOVX
Theriva Biologics
|
-- | -$4.6M | -- | -- | -- | -$4.7M |
Outlook Therapeutics vs. Competitors
-
Which has Higher Returns OTLK or BMRA?
Biomerica has a net margin of -- compared to Outlook Therapeutics's net margin of -58.07%. Outlook Therapeutics's return on equity of -- beat Biomerica's return on equity of -81.84%.
Company Gross Margin Earnings Per Share Invested Capital OTLKOutlook Therapeutics-- $0.72 -- BMRABiomerica26.71% -$0.06 $5.1M -
What do Analysts Say About OTLK or BMRA?
Outlook Therapeutics has a consensus price target of $10.00, signalling upside risk potential of 536.94%. On the other hand Biomerica has an analysts' consensus of -- which suggests that it could grow by 1963.17%. Given that Biomerica has higher upside potential than Outlook Therapeutics, analysts believe Biomerica is more attractive than Outlook Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings OTLKOutlook Therapeutics4 1 0 BMRABiomerica0 0 0 -
Is OTLK or BMRA More Risky?
Outlook Therapeutics has a beta of 0.539, which suggesting that the stock is 46.056% less volatile than S&P 500. In comparison Biomerica has a beta of -1.163, suggesting its less volatile than the S&P 500 by 216.324%.
-
Which is a Better Dividend Stock OTLK or BMRA?
Outlook Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biomerica offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Outlook Therapeutics pays -- of its earnings as a dividend. Biomerica pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OTLK or BMRA?
Outlook Therapeutics quarterly revenues are --, which are smaller than Biomerica quarterly revenues of $1.6M. Outlook Therapeutics's net income of $17.4M is higher than Biomerica's net income of -$950K. Notably, Outlook Therapeutics's price-to-earnings ratio is -- while Biomerica's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Outlook Therapeutics is 4.23x versus 1.91x for Biomerica. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OTLKOutlook Therapeutics4.23x -- -- $17.4M BMRABiomerica1.91x -- $1.6M -$950K
-
Which has Higher Returns OTLK or NBY?
NovaBay Pharmaceuticals has a net margin of -- compared to Outlook Therapeutics's net margin of -49.65%. Outlook Therapeutics's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.
Company Gross Margin Earnings Per Share Invested Capital OTLKOutlook Therapeutics-- $0.72 -- NBYNovaBay Pharmaceuticals65.26% -$0.60 $1.1M -
What do Analysts Say About OTLK or NBY?
Outlook Therapeutics has a consensus price target of $10.00, signalling upside risk potential of 536.94%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 34.9%. Given that Outlook Therapeutics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Outlook Therapeutics is more attractive than NovaBay Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings OTLKOutlook Therapeutics4 1 0 NBYNovaBay Pharmaceuticals1 0 0 -
Is OTLK or NBY More Risky?
Outlook Therapeutics has a beta of 0.539, which suggesting that the stock is 46.056% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.726, suggesting its less volatile than the S&P 500 by 27.362%.
-
Which is a Better Dividend Stock OTLK or NBY?
Outlook Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Outlook Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OTLK or NBY?
Outlook Therapeutics quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Outlook Therapeutics's net income of $17.4M is higher than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Outlook Therapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Outlook Therapeutics is 4.23x versus 0.07x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OTLKOutlook Therapeutics4.23x -- -- $17.4M NBYNovaBay Pharmaceuticals0.07x -- $2.4M -$1.2M
-
Which has Higher Returns OTLK or OGEN?
Oragenics has a net margin of -- compared to Outlook Therapeutics's net margin of --. Outlook Therapeutics's return on equity of -- beat Oragenics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital OTLKOutlook Therapeutics-- $0.72 -- OGENOragenics-- -$0.38 -- -
What do Analysts Say About OTLK or OGEN?
Outlook Therapeutics has a consensus price target of $10.00, signalling upside risk potential of 536.94%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 257.14%. Given that Outlook Therapeutics has higher upside potential than Oragenics, analysts believe Outlook Therapeutics is more attractive than Oragenics.
Company Buy Ratings Hold Ratings Sell Ratings OTLKOutlook Therapeutics4 1 0 OGENOragenics0 1 0 -
Is OTLK or OGEN More Risky?
Outlook Therapeutics has a beta of 0.539, which suggesting that the stock is 46.056% less volatile than S&P 500. In comparison Oragenics has a beta of 0.847, suggesting its less volatile than the S&P 500 by 15.305%.
-
Which is a Better Dividend Stock OTLK or OGEN?
Outlook Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Outlook Therapeutics pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OTLK or OGEN?
Outlook Therapeutics quarterly revenues are --, which are smaller than Oragenics quarterly revenues of --. Outlook Therapeutics's net income of $17.4M is higher than Oragenics's net income of -$2.5M. Notably, Outlook Therapeutics's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Outlook Therapeutics is 4.23x versus 1.10x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OTLKOutlook Therapeutics4.23x -- -- $17.4M OGENOragenics1.10x -- -- -$2.5M
-
Which has Higher Returns OTLK or PTN?
Palatin Technologies has a net margin of -- compared to Outlook Therapeutics's net margin of -2357.27%. Outlook Therapeutics's return on equity of -- beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital OTLKOutlook Therapeutics-- $0.72 -- PTNPalatin Technologies-- -$0.12 -$111.5K -
What do Analysts Say About OTLK or PTN?
Outlook Therapeutics has a consensus price target of $10.00, signalling upside risk potential of 536.94%. On the other hand Palatin Technologies has an analysts' consensus of $7.00 which suggests that it could grow by 785.18%. Given that Palatin Technologies has higher upside potential than Outlook Therapeutics, analysts believe Palatin Technologies is more attractive than Outlook Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings OTLKOutlook Therapeutics4 1 0 PTNPalatin Technologies0 0 0 -
Is OTLK or PTN More Risky?
Outlook Therapeutics has a beta of 0.539, which suggesting that the stock is 46.056% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.793, suggesting its less volatile than the S&P 500 by 20.66%.
-
Which is a Better Dividend Stock OTLK or PTN?
Outlook Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Outlook Therapeutics pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OTLK or PTN?
Outlook Therapeutics quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of $350K. Outlook Therapeutics's net income of $17.4M is higher than Palatin Technologies's net income of -$2.4M. Notably, Outlook Therapeutics's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Outlook Therapeutics is 4.23x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OTLKOutlook Therapeutics4.23x -- -- $17.4M PTNPalatin Technologies-- -- $350K -$2.4M
-
Which has Higher Returns OTLK or TOVX?
Theriva Biologics has a net margin of -- compared to Outlook Therapeutics's net margin of --. Outlook Therapeutics's return on equity of -- beat Theriva Biologics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital OTLKOutlook Therapeutics-- $0.72 -- TOVXTheriva Biologics-- -$1.60 -- -
What do Analysts Say About OTLK or TOVX?
Outlook Therapeutics has a consensus price target of $10.00, signalling upside risk potential of 536.94%. On the other hand Theriva Biologics has an analysts' consensus of $6.00 which suggests that it could grow by 419.93%. Given that Outlook Therapeutics has higher upside potential than Theriva Biologics, analysts believe Outlook Therapeutics is more attractive than Theriva Biologics.
Company Buy Ratings Hold Ratings Sell Ratings OTLKOutlook Therapeutics4 1 0 TOVXTheriva Biologics0 0 0 -
Is OTLK or TOVX More Risky?
Outlook Therapeutics has a beta of 0.539, which suggesting that the stock is 46.056% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.159, suggesting its more volatile than the S&P 500 by 15.945%.
-
Which is a Better Dividend Stock OTLK or TOVX?
Outlook Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Outlook Therapeutics pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OTLK or TOVX?
Outlook Therapeutics quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. Outlook Therapeutics's net income of $17.4M is higher than Theriva Biologics's net income of -$4.4M. Notably, Outlook Therapeutics's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Outlook Therapeutics is 4.23x versus 1.59x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OTLKOutlook Therapeutics4.23x -- -- $17.4M TOVXTheriva Biologics1.59x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Qualcomm Stock: 5G Leader at a Bargain Price?
Chip giant QUALCOMM Incorporated (NASDAQ:QCOM) was the ultimate chip company…
What Is Buffett Buying and Selling Now?
In Q4 of last year, Warren Buffett made a few…
Stock Ideas
Buy
52
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
56
Is NVDA Stock a Buy?
Market Cap: $3T
P/E Ratio: 41x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Alerts
Buy
59
GRRR alert for Mar 15
Gorilla Technology Group [GRRR] is up 29.72% over the past day.
Sell
49
SMTC alert for Mar 15
Semtech [SMTC] is up 21.28% over the past day.
Buy
62
PLPC alert for Mar 15
Preformed Line Products [PLPC] is up 17.38% over the past day.
